| Trial Identifier: | HPN217-3001 |
| Sponsor: | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Start Date: | April 2020 |
| Primary Completion Date: | June 2025 |
| Study Completion Date: | November 2025 |
| Condition: | Myeloma |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| Protocol Plain Language Summary – English |
| Country | Location |
|---|---|
| France | Nantes, France, 44093 |
| France | Poitiers, France, 86021 |
| Spain | Barcelona, Spain, 08916 |
| Spain | Madrid, Spain, 28040 |
| United States, Arizona | Gilbert, Arizona, United States, 85234 |
| United States, Arizona | Phoenix, Arizona, United States, 85054 |
| United States, California | La Jolla, California, United States, 92093 |
| United States, Kansas | Fairway, Kansas, United States, 66205 |
| United States, New York | Buffalo, New York, United States, 14263 |
| United States, New York | Rochester, New York, United States, 14642 |
| United States, Oregon | Portland, Oregon, United States, 97239 |
| United States, Washington | Seattle, Washington, United States, 98109 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company